Biomedicine enters a new "Golden Decade"

In 2020, the epidemic broke out, the international situation was severe, and the global economy was down.
However, China's biomedical industry relied on the opportunities brought by continuous policy reforms to burst out innovative vitality in the face of adversity: the structure of the new crown virus was analyzed in the first time, and the diagnostic reagents were quickly developed.
The products are put into the front line of epidemic prevention, the parallel R&D of vaccines with multiple technologies is at the forefront of the world, a number of local innovative drugs have successfully entered the world, and the number of overseas authorized cooperation projects and the total transaction volume have reached record highs.
.
.
The development momentum is like a rainbow
.

It is undeniable that the new crown epidemic has accelerated the rapid development and transformation of the entire biomedical technology industry.
A batch of new technology companies on the track of subdivisions have emerged.
The industry generally believes that China's biomedical industry will rush to the next ten years.
Over the past ten years, the previous ten years are an accumulation, and the next ten years begin to exert strength
.

01 Pharmaceutical policy reform to speed up drug approval

The pharmaceutical policy reform that began in 2015 has greatly accelerated the research and development of new biological drugs in China, cracked down on data fraud, resolved the backlog of reviews, improved standards for generic drugs and new drugs, streamlined the approval process, accelerated drug approval, encouraged and supported innovation, and stepped up to international standards.
, The data in the "Report Card for the Fifth Anniversary of the Drug Review Reform" is sufficient to show that the drug policy reform has achieved great results
.

The backlog of reviews has been greatly improved: the number of registration applications waiting to be reviewed has been reduced from 22,000 at the peak of 2015 to more than 4,000 now
.

02 Government support to accelerate the biopharmaceutical industry cluster

Biomedicine, as one of the seven strategic emerging industries identified in China, has received unprecedented attention.
Biomedical industry clusters have been formed in the Bohai Sea, the Yangtze River Delta, the Pearl River Delta and the central and western regions, and various localities have launched to promote the development of biomedicine.
Under the catalysis of policy, technology, capital and other factors, biomedicine has become the core engine for the high-quality economic development of many industrial parks
.

In the past, the traditional superiority parks of the domestic biopharmaceutical industry were mainly concentrated in the Beijing-Tianjin-Hebei, Yangtze River Delta and Pearl River Delta regions, showing a "three-legged" situation.
Due to the influence of many factors such as carrying capacity, production and living costs, and enterprise spillover tendencies, the original three-legged pattern It is gradually evolving into seven urban agglomerations leading the development of the biomedical industry, namely, the Beijing-Tianjin-Hebei urban agglomeration, the Yangtze River Delta urban agglomeration, the Pearl River Delta urban agglomeration, the Yangtze River midstream urban agglomeration, the Central Plains urban agglomeration, the Sichuan-Chongqing urban agglomeration, and the Guanzhong Plain urban agglomeration
.

Beijing, Shanghai, Guangzhou, Shenzhen, Suzhou, Hangzhou, Nanjing, Chengdu, Wuhan and other highly representative and potential development cities and other cities around the world have introduced relevant support policies to promote the development of the biopharmaceutical industry: from talent introduction, innovative research and development , Public service platforms, professional technology platforms, incubators, crowd-creation space, achievement transformation, international market development, clinical institution cultivation, financial capital services, scientific and technological innovation support, talent entrepreneurship funding, and other aspects of support are unprecedented
.

03 Capital opening, biomedicine embarks on a bull market journey

Biomedicine is known as the never-ending "sunrise industry".
With the global outbreak of the new crown epidemic, companies in the health sector have developed rapidly, bringing in more capital
.

In the context of the influx of capital, it has become easier to attract talents.
In particular, the epidemic situation abroad is severe and the wind is tight, and talents from the biomedical industry and academia continue to return to the country
.

In the next ten years, with the acceleration of aging, the demand side of the industry will explode rapidly, the accumulation of the industry in the early stage, the promotion of industrial capital, the rapid emergence of policy-oriented results, and the growing strength of supporting industries will surely make the entire industry From imitation/following to innovation, domestic substitution of imports, domestic to international, the biomedical industry will enter an unprecedented "golden decade"